Search
Search Results
-
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study
BackgroundMET exon 14 skip** mutations occur in 3–4% and MET high amplifications occur in < 1% of patients with non-small-cell lung cancer...
-
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
Genomic MET amplification and exon 14 skip** are currently clinically recognized biomarkers for stratifying subsets of non-small cell lung cancer...
-
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer
MET amplification/mutations are important targetable oncogenic drivers in NSCLC, however, acquired resistance is inevitable and the majority of...
-
A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer
Previously, we generated a novel bispecific antibody (BsAb) simultaneously targeting both c-MET and PD-1 (PDCD1), which can bridge T cells and c-MET...
-
Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skip** mutation, MET overexpression and amplification
PurposeMET exon 14 skip** is one of the rare mutations in non-small cell lung cancer (NSCLC), involving its pathogenesis and progression. The...
-
ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma
BackgroundSustained activation of hepatocyte growth factor (HGF)/c-MET signaling is a major driver of hepatocellular carcinoma (HCC) progression, but...
-
MET fusions and splicing variants convergently define a subgroup of glioma sensitive to MET inhibitors
PurposeOur previous study has shown that PTPRZ1-MET (ZM) fusion is a viable target for MET inhibitors in gliomas. However, the diversity and...
-
Evaluation of molecular residual disease in operable non-small cell lung cancer with gene fusions, MET exon skip** or de novo MET amplification
Gene fusions and MET alterations are rare and difficult to detect in plasma samples. The clinical detection efficacy of molecular residual disease...
-
Deregulated immune cell recruitment orchestrated by c-MET impairs pulmonary inflammation and fibrosis
BackgroundPulmonary fibrosis (PF) represents the pathologic end stage of several interstitial lung diseases (ILDs) associated with high morbidity and...
-
MET receptor serves as a promising target in melanoma brain metastases
The development of brain metastases hallmarks disease progression in 20–40% of melanoma patients and is a serious obstacle to therapy. Understanding...
-
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance
MET exon 14 skip** alterations and MET amplifications are recognized as oncogenic and targetable genetic changes in cancer patients. The treatment...
-
Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors
Small molecule mesenchymal-epithelial transition (MET) inhibitors, such as crizotinib, capmatinib, and tepotinib, are treatment options for...
-
-
Kortdurende exposuretherapie voor jongeren met een specifieke angst Handleiding voor de therapeut
Dit behandelprotocol beschrijft hoe kortdurende exposuretherapie kan worden toegepast bij jongeren van 12 tot 18 jaar bij wie een specifieke fobie is...
-
-
Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations
BackgroundMesenchymal epithelial transition factor (MET) is a rare oncologic driver gene, and information on immunotherapy for non-small cell lung...
-
MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study
BackgroundAbout 50–60% treatment-naïve advanced non-small-cell lung cancers were coexistence of epidermal growth factor receptor (EGFR) and...
-
Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring MET amplification
Neuroendocrine carcinoma (NEC) of the gallbladder origin is particularly rare, accounting for only 0.38% of primary malignancies of the gallbladder,...
-
-
